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Despite recent advances in medicine, including the molecu-
lar and genetic advances in the ﬁeld of oncology, glioblas-
toma remains one of the deadliest cancers in humans.
Advances over the past 30 years have led to measurable
but modest improvement in survival. New approaches
to treatment, including vaccine therapy, based on sound
laboratory and preclinical data, are encouraging, but the key
to a substantial impact in patients with glioblastoma has
remained elusive.
This special issue was undertaken in an eﬀort to demon-
strate some of the novel approaches to basic science, diag-
nosis, and treatment for patients with glioblastoma. The ﬁrst
manuscript discuses the use of a leading edge MR imaging
technique, texture analysis, to diﬀerentiate glioblastoma
from malignant glioneuronal tumors, highlighting advanced
imaging techniques that should be further explored across
brain tumors.
Basic science advances are also discussed. One article
discusses the cause/eﬀect role of leptin in glioblastoma, with
a discussion regarding a potentially central role in tumor
progression. In addition, E. A. El Habr et al. elucidate the
clinical and prognostic role of the AKT-mTOR pathway in
astrocytomas. These basic science developments are impor-
tant as clinically relevant therapies are developed by logical
extension from basic and translational knowledge.
Two other manuscripts focus on current and future
trends in the management of glioblastoma. While the out-
comes for patients with this deadly disease remain poor, it
is our sincere hope that the work and eﬀort demonstrated
by our authors, and scores of researchers around the world,
will lead to substantial advances in our understanding and
management of glioblastoma.
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